top
London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’
Why this matters: a developing story that could shape the day's news cycle.
Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading...
Article preview — originally published by The Guardian. Full story at the source.
Read full story on The Guardian →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from The Guardian alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop